![An Bang Lu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
An Bang Lu
Chief Executive Officer at VISEN Pharmaceuticals
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jan Mikkelsen | M | 65 |
VISEN Pharmaceuticals
![]() VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
![]() VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | 6 years |
Hong Ni | F | 52 |
VISEN Pharmaceuticals
![]() VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | 3 years |
Zheng Bin Yao | M | 58 |
VISEN Pharmaceuticals
![]() VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | 3 years |
Michael Wolff Jensen | M | 53 |
VISEN Pharmaceuticals
![]() VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
![]() VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | 3 years |
Shan Fu | M | 56 |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
![]() VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction.
VISEN Pharmaceuticals
![]() VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | 6 years |
Peng Kuan Chan | M | 60 |
VISEN Pharmaceuticals
![]() VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | 3 years |
Dan Dan Dong | M | 40 |
VISEN Pharmaceuticals
![]() VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
![]() VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | 6 years |
Yi Bo Cao | M | 42 |
VISEN Pharmaceuticals
![]() VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
![]() VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | 3 years |
Mwana Lugogo | M | 54 | 12 years | |
Sze Ting Chan | F | 42 |
VISEN Pharmaceuticals
![]() VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | - |
Christopher O'Reilly | M | - | 13 years | |
Jun Yang | M | 52 |
VISEN Pharmaceuticals
![]() VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | 4 years |
Jun Chen | M | 54 |
VISEN Pharmaceuticals
![]() VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Iwaaki Taniguchi | M | - | - | |
Shiro Kuniya | M | 67 | - | |
Deborah Dunsire | M | 61 | 3 years | |
Yorihiko Kojima | M | 82 | - | |
Tadataka Yamada | M | 78 | 4 years | |
Frank Morich | M | 69 | 4 years | |
Fumio Sudo | M | 83 | 6 years | |
François-Xavier Roger | M | 62 | 2 years | |
Jessica Sachs | M | 49 | 5 years | |
Sigurd Okkels | M | - | 6 years | |
Azmi Nabulsi | M | 64 | 4 years | |
Stephen Brannan | M | 67 | 4 years | |
Ai Min Hui | M | 61 | 5 years | |
Tom Harris | M | - | 7 years | |
Timothy Sullivan | M | 54 | 3 years | |
Mikuno Furuta | M | - | - | |
Quentin McCubbin | M | 54 | 7 years | |
Yan Zhu | M | 60 | 2 years | |
Jamie Dananberg | M | 66 | 3 years | |
Futoshi Sanematsu | M | - | - | |
Claudio Dansky Ullmann | M | - | 3 years | |
Ralf Clemens | M | 71 | 3 years | |
Satoshi Adachi | M | - | - | |
Tetsuo Miwa | M | - | - | |
Yoshiaki Nomura | M | - | - | |
Karen Ferrante | M | 66 | 6 years | |
Jostein Davidsen | M | 65 | 3 years | |
Michael Martin | M | 50 | 3 years | |
James O'Brien | M | 57 | - | |
Yuji Iizawa | M | - | 4 years | |
Anna Protopapas | F | 59 | 4 years | |
Elena Cant | F | 47 | 7 years |
Statistics
Country | Connections | % of total |
---|---|---|
Japan | 34 | 75.56% |
China | 11 | 24.44% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- An Bang Lu
- Personal Network